Octyl Gallate Markedly Promotes Anti-Amyloidogenic Processing of APP through Estrogen Receptor-Mediated ADAM10 Activation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, She Qing ^a,b   Sawmiller, Darrell ^a,c   Li, Song ^a,d   Rezai Zadeh, Kavon ^a   Hou, Huayan ^a   Zhou, Shufeng ^e   Shytle, Douglas ^a   Giunta, Brian ^a,c   Fernandez, Frank ^a   Mori, Takashi ^f   Tan, Jun ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ATRANORIN; CATECHIN; EPICATECHIN; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; GALLIC ACID BUTYL ESTER; GALLIC ACID METHYL ESTER; GALLIC ACID OCTYL ESTER; GALLIC ACID PROPYL ESTER; GALLOCATECHIN; PHENOL; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTI AMYLOIDOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING;

ADAM PROTEINS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GALLIC ACID; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84881571576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071913     Document Type: Article

References (31)

1. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502, 172-187.
2. Huse JT, Doms RW (2000) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 22, 81-98.
3. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the β-amyloid protein in Alzheimer's disease. Neuromolecular Med 1, 1-31.
4. Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, et al. (2004) Truncated carboxyl-terminal fragments of β-amyloid precursor protein are processed to amyloid β-proteins 40 and 42. Biochemistry 43, 13532-13540.
5. Sinha S, Lieberburg I (1999) Cellular mechanisms of β-amyloid production and secretion. Proc Natl Acad Sci U S A 96, 11049-11053.
6. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
7. Steiner H, Capell A, Haass C (1999) Proteolytic processing and degradation of Alzheimer's disease relevant proteins. Biochem Soc Trans 27, 234-242.
8. Hooper NM, Turner AJ (2002) The search for α-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 9, 1107-1119.
9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
10. Lin JK, Liang YC (2000) Cancer chemoprevention by tea polyphenols. Proc Natl Sci Counc Repub China B 24, 1-13.
11. Moyers SB, Kumar NB (2004) Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62, 204-211.
12. Levites Y, Amit T, Youdim MB, Mandel S (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 277, 30574-30580.
13. Levites Y, Amit T, Mandel S, Youdim MB (2003) Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 17, 952-954.
14. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, et al. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25, 8807-8814.
15. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, et al. (2006) ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced α-secretase cleavage of amyloid precursor protein. J Biol Chem 281, 16419-16427.
16. Miller D, Wheals BB, Beresford N, Sumpter JP (2001) Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay. Environ Health Perspect 109, 133-138.
17. Fang H, Tong W, Shi LM, Blair R, Perkins R, et al. (2001) Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 14, 280-294.
18. Fernandez JW, Rezai-Zadeh K, Obregon D, Tan J (2010) EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FEBS Lett 584, 4259-4267.
19. Tan J, Town T, Paris D, Mori T, Suo Z, et al. (1999) Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 286, 2352-2355.
20. Tan J, Town T, Crawford F, Mori T, DelleDonne A, et al. (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5, 1288-1293.
21. Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, et al. (2004) Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 109, 2448-2453.
22. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, et al. (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471, 134-138.
23. Hooper NM, Turner AJ (2002) The search for α-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 9, 1107-1119.
24. Mannella P, Brinton RD (2006) Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. J Neurosci 26, 9439-9447.
25. Zhao L, Brinton RD (2007) Estrogen receptor α and β differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res 1172, 48-59.
26. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113, 1456-1464.
27. Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL (1995) Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1, 829-832.
28. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, et al. (2000) Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 278, 169-172.
29. Han X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2, 65-77.
30. Baum LW (2005) Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 60, 736-743.
31. Musicco M (2009) Gender differences in the occurrence of Alzheimer's disease. Funct Neurol 24, 89-92.